Neurotoxicity following chimeric antigen receptor T-cell therapy is associated with astrocyte injury

Lire cet article en français

Takeaway

  • Astrocyte injury during neurotoxicity was observed in individuals receiving CD19-directed chimeric antigen receptor T-cell therapy (CAR-T). However, the exact role of the glia in immune effector cell-associated neurotoxicity syndrome (ICANS) pathogenesis is yet to be determined.

Why this matters

  • Systemic cytokine release syndrome (CRS) and neurotoxicity following CAR-T treatment are complications that can sometimes be fatal. This study attempts to understand the mechanism of ICANS to develop better preventative and therapeutic measures.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.